Last reviewed · How we verify

(Part C) MET097 (part-c-met097)

Pfizer · FDA-approved active Quality 37/100

The exact mechanism of action is not specified on Wikipedia.

Part C) MET097, developed by Pfizer, holds a significant market position with 116 approved indications, though it has not yet entered clinical trials. Its competitive advantage is somewhat unclear due to the lack of specified mechanism of action and revenue data, but it faces strong competition from drugs like Ozempic, Rybelsus, Mounjaro, Januvia, and Victoza, which have well-defined mechanisms and established markets. A key risk for Part C) MET097 is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its accessibility and broaden its target patient population. The pipeline outlook remains uncertain without ongoing or planned clinical trials, raising questions about its future development and commercial viability.

At a glance

Generic namepart-c-met097
SponsorPfizer
Drug classUnknown
TargetUnknown
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Unfortunately, there is limited information available on the mechanism of action of MET097. As a result, it is difficult to provide a detailed explanation of how the drug works. Further research is needed to fully understand the mechanism of action of MET097.

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: